Does BPH Raise Prostate Cancer Risk? How to Tell Them Apart

Having Benign Prostatic Hyperplasia (BPH) does not mean you will get prostate cancer, and BPH does not transform into cancer ^[1]. However, because both conditions are very common as men age, they frequently exist at the same time ^[2]. Having BPH does not protect you from developing prostate cancer, so BPH-related symptoms or elevated test results should not be assumed to be cancer—or assumed not to be cancer—without appropriate evaluation ^[3].

Two Distinct Conditions

Although both BPH and prostate cancer involve the prostate gland growing, they are fundamentally different disease processes.

• BPH is a non-cancerous enlargement that typically occurs in the transition zone (the inner part of the prostate surrounding the urethra) ^[4]. Because of its location, BPH commonly causes urinary symptoms by squeezing the urethra.
• Prostate cancer most often begins in the peripheral zone (the outer area of the prostate) and is a malignant (cancerous) growth that can spread to other parts of the body ^[4].

While observational studies show the two conditions share some susceptibility factors—like age and inflammation—evidence supports that BPH is not a direct stepping stone to cancer ^[5][1].

Do You Still Need Cancer Screening?

BPH does not automatically change whether prostate cancer screening is appropriate for you, but whether and when to screen remains a highly individualized decision ^[3]. Screening recommendations vary based on the specific guidelines being used, your age, life expectancy, and your baseline risk (such as having first-degree relatives with prostate cancer or high-risk ancestry) ^[3].

Because prostate cancer screening involves a trade-off, you and your doctor should make a shared decision. The goal is to balance the benefit of catching a dangerous cancer early against the risks of overdiagnosis—which means finding a slow-growing cancer that would never have caused you harm during your lifetime—and unnecessary medical procedures ^[3].

How Doctors Tell Them Apart

Because a single test cannot reliably separate BPH from cancer, doctors use a step-by-step diagnostic sequence. This often involves reviewing your symptoms and medications, confirming prostate-specific antigen (PSA) levels, calculating your overall risk, and then selectively using advanced imaging or a biopsy.

Symptoms Are Not Enough

You cannot tell the difference between BPH and prostate cancer based on symptoms alone ^[6]. BPH commonly causes lower urinary tract symptoms (LUTS) like a weak stream, frequent urination, and difficulty emptying the bladder ^[6]. Early prostate cancer often causes no symptoms at all.

When to Seek Urgent Care: While worsening urinary symptoms do not necessarily mean cancer, certain “red flag” symptoms require prompt medical attention:

• A sudden, painful inability to urinate (acute urinary retention) is a urological emergency that requires immediate intervention, such as catheterization ^[7].
• Visible blood in the urine warrants prompt medical evaluation ^[8].
• Fever and chills accompanied by urinary symptoms could indicate a severe infection requiring urgent treatment ^[9].

The Digital Rectal Exam (DRE)

During a DRE, a doctor feels the prostate to check its size, shape, and texture. An enlarged, smooth prostate is typical of BPH. If the doctor feels a hard nodule or asymmetry, it is considered a suspicious finding that warrants further investigation ^[10]. However, a DRE is just one part of the assessment ^[11]. A normal DRE cannot completely rule out prostate cancer, and an abnormal DRE is not proof of cancer.

PSA Tests and Crucial Medications

Prostate-Specific Antigen (PSA) is a protein produced by the prostate. While a high PSA can be a sign of cancer, BPH also causes the prostate to produce more PSA, making the test less straightforward ^[12].

Because PSA naturally fluctuates and can be elevated by recent urinary procedures, urinary retention, or infection, doctors rarely rely on a single reading or the speed at which it rises (PSA velocity) in isolation ^[12]. Instead, they typically repeat the test to confirm a trend and consider PSA density—your PSA level divided by the volume (size) of your prostate ^[13].

Important Medication Warning: Medications commonly prescribed for BPH, such as 5-alpha reductase inhibitors (finasteride and dutasteride), lower PSA levels by approximately 50% within 6 to 12 months of starting them ^[14]. If your doctor does not know you are taking these medications, they may fail to adjust for this artificial drop, potentially delaying the evaluation of a concerning PSA result ^[15]. Always provide an accurate medication history.

Advanced Imaging (mpMRI) and Biopsy

If your PSA levels or DRE are concerning, your doctor will likely recommend further evaluation before jumping straight to a biopsy.

• Multiparametric MRI (mpMRI): This specialized imaging scan helps identify suspicious areas in the prostate and is scored using a system called PI-RADS ^[16]. A negative MRI reduces the risk of having a clinically significant cancer, but it does not eliminate it entirely, so follow-up may still be needed depending on your overall clinical picture ^[3].
• Prostate Biopsy: If an MRI shows high-risk areas (a high PI-RADS score) or other clinical risks are high, a biopsy may be recommended. This involves taking small tissue samples and is the only definitive way to confirm whether cancer cells are present ^[17]. Biopsies carry risks—such as bleeding, infection, and temporary urinary difficulties—which is why they are only used when carefully selected ^[3].